Comparative Pharmacology
Head-to-head clinical analysis: EMPAVELI versus ENJAYMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMPAVELI versus ENJAYMO.
EMPAVELI vs ENJAYMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pegcetacoplan is a complement C3 inhibitor that binds to complement component C3 and its activation fragment C3b, thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation.
ENJAYMO (sutimlimab-jome) is a monoclonal antibody that binds to complement component C1s and inhibits the activation of the classical complement pathway. This prevents the destruction of red blood cells, platelets, and endothelial cells by the complement system.
1080 mg subcutaneously once weekly for 2 weeks, then 1080 mg subcutaneously every 2 weeks thereafter.
600 mg subcutaneous injection once weekly for 4 weeks, followed by 900 mg every 2 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 7-10 days. This supports once-weekly subcutaneous dosing, achieving steady-state concentrations after 3-4 weeks of weekly administration.
6-8 days (terminal half-life); prolonged due to FcRn binding, allowing monthly dosing
Primarily excreted unchanged in urine (approximately 60-70% of administered dose) and feces (approximately 20-30% as parent drug and metabolites). Less than 1% is recovered as metabolites.
Renal: <1% unchanged; primarily eliminated via FcRn-mediated catabolism; no biliary/fecal excretion data
Category C
Category C
Complement Inhibitor
Complement Inhibitor